Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX in Advanced High-Grade Neuroendocrine Neoplasms
NCT07077551Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in neuroendocrine neoplasms (NENs), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT07077551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077551.